Abstract

In the present study, we investigated if the intracellular Cl<sup>-</sup> affects cell growth and cell cycle progression of androgen-independent prostate cancer PC3 cells. PC3 cells cultured in a medium containing 113 mM Cl<sup>-</sup> for 96 h grew up 9-fold in cell number, while PC3 cells cultured in an 8 mM-Cl<sup>-</sup>-containing culture medium showed complete arrest of cell growth even after culture for 96 h. Exposure of cells to the 8 mM-Cl<sup>-</sup> culture medium diminished phosphorylation levels of Rb and cdc2, which are respectively key accelerators of transition from G<sub>1</sub> to S phase and G<sub>2</sub> to M phase in cell cycle progression. Culturing cells in the 8 mM-Cl<sup>-</sup>-containing culture medium upregulated the protein expression level of p21 (a CDK inhibitor) inhibiting transition of G<sub>1</sub> to S phase, and diminished the incorporation of 5-ethynyl-2′-deoxyuridine (EdU; a thymidine analogue) into DNA. These results suggest that cells cultured in the low Cl<sup>-</sup> medium prolonged the duration of all phases of the cell cycle (G<sub>1</sub>, S, and G<sub>2</sub>/M), thereby abolishing overall cell cycle progression. Effects of culturing cells in the low Cl<sup>-</sup> culture medium on cell cycle progression would be mediated via a change in the intracellular Cl<sup>-</sup> concentration ([Cl<sup>-</sup>]<sub>i</sub>), since [Cl<sup>-</sup>]<sub>i</sub> was decreased under a low Cl<sup>-</sup> culture medium. To clarify this possibility, we studied effects of furosemide and bumetanide, Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> cotransporter (NKCC) inhibitors, on proliferation of PC3 cells. Furosemide and bumetanide decreased [Cl<sup>-</sup>]<sub>i</sub> and cell growth of PC3 cells. These results suggest that a change in [Cl<sup>-</sup>]<sub>i</sub> would play a critical role in this growth mechanism.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.